Last reviewed · How we verify
NCT01595113
A Follow-up Observational Study of Safety of Clinical Trial Conducted With Cell Transplant Therapy Using Hearticellgram-AMI for Patients With Acute Myocardial Infarction
trial in Acute Myocardial Infarction in 41 participants. Completed in 1 December 2012.
1 October 2012
Quick facts
| Lead sponsor | Pharmicell Co., Ltd. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 41 |
| Start date | 1 May 2012 |
| Primary completion | 1 October 2012 |
| Estimated completion | 1 December 2012 |
Conditions studied
- Acute Myocardial Infarction — all drugs for Acute Myocardial Infarction →
Sponsor
Pharmicell Co., Ltd. — full company profile →
Who can join
Adults 18 to 80, any sex, with Acute Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the safety of the previously conducted clinical trial cell transplant therapy using Hearticellgram-AMI for patients with acute myocardial infarction. This is a follow-up observational study and targeting the subjects who participated in the previously conducted clinical trial.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT01595113
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Acute Myocardial Infarction
Currently open trials in the same condition.
- NCT03951467 — Using an Intervention Adapted to the Health Literacy Level to Improve Adherence to Medical Recommendations · NA · recruiting
- NCT07536802 — Adenosine Pre-Medication in Primary Percutaneous Coronary Intervention: A Randomized Control Trial · Phase 4 · recruiting
- NCT06947135 — Stellate Ganglion Morphine Infiltration on Myocardial Ischemia-Reperfusion Injury · NA · recruiting
- NCT06515730 — Treatment With Apixaban Versus Warfarin in Patients With Left Ventricular Thrombus After Acute Myocardial Infarction · Phase 4 · recruiting
- NCT07522164 — Acute Myocardial Infarction Clinical Cohort · active not recruiting
Other Pharmicell Co., Ltd. trials
Trials by the same sponsor.
- NCT07431008 — Safety Follow-up Study of Cellgram-ED in Post-Radical Prostatectomy Erectile Dysfunction · recruiting
- NCT07400458 — Long-term Follow-up Study Following the Approval of Hearticellgram-AMI Administration · NA · recruiting
- NCT05042206 — Clinical Trial to Evaluate Safety of Allogeneic Bone Marrow Derived Mesenchymal Stem Cell in Chronic Kidney Disease · Phase 1 · completed
- NCT05093881 — Long-term Follow-up of Patients With Alcoholic Liver Cirrhosis Who Had Administered Cellgram-LC in PMC-P-07 Study · NA · recruiting
- NCT04615845 — Safety Evaluation of Autologous Dendritic Cell Anticancer Immune Cell Therapy (Cellgram-DC-PC) · Phase 1 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT01595113 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pharmicell Co., Ltd.
- Last refreshed: 11 February 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01595113.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing